Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
12,720
+310 (2.50%)
At close: Mar 27, 2025, 3:30 PM KST

Prestige BioPharma Income Statement

Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20
Revenue
5,869689.08161.84---
Revenue Growth (YoY)
1582.73%325.77%----
Cost of Revenue
1,2181,21833.94228.95284.85123.87
Gross Profit
4,651-528.79127.9-228.95-284.85-123.87
Selling, General & Admin
51,52645,47658,23154,42216,4329,564
Operating Expenses
67,76061,709-906.28122,46018,09912,769
Operating Income
-63,109-62,2381,034-122,689-18,384-12,893
Interest Expense
-7,404-7,404-950.8-18.85-6.2-
Interest & Investment Income
12,40212,40210,4642,729158.22523.21
Earnings From Equity Investments
---16.96---
Currency Exchange Gain (Loss)
-4,232-4,232-924.24-1,592-4,62057.88
Other Non Operating Income (Expenses)
3,7226,6934,0342,282414.8-1,986
EBT Excluding Unusual Items
-58,620-54,77913,639-119,288-22,437-14,299
Gain (Loss) on Sale of Investments
----15,081-
Gain (Loss) on Sale of Assets
89.489.472.12211.59-0.36-
Asset Writedown
---15,807-91,573--599.83
Pretax Income
-58,531-54,689-2,095-210,649-7,357-14,898
Income Tax Expense
284.99408.68763.28800.6634.0898.47
Earnings From Continuing Operations
-58,816-55,098-2,859-211,450-7,391-14,997
Minority Interest in Earnings
28,96222,17720,428---
Net Income
-29,854-32,92117,569-211,450-7,391-14,997
Net Income to Common
-29,854-32,92117,569-211,450-7,391-14,997
Shares Outstanding (Basic)
606060605243
Shares Outstanding (Diluted)
606060605243
Shares Change (YoY)
-0.12%--16.46%20.98%-
EPS (Basic)
-496.51-547.81292.35-3518.53-143.23-351.60
EPS (Diluted)
-496.51-547.81292.35-3796.17-143.23-351.60
Free Cash Flow
-91,000-68,091-108,636-102,336-16,396-13,761
Free Cash Flow Per Share
-1513.45-1133.03-1807.71-1702.88-317.73-322.63
Gross Margin
79.25%-76.74%79.03%---
Operating Margin
-1075.25%-9032.13%639.01%---
Profit Margin
-508.65%-4777.60%10855.90%---
Free Cash Flow Margin
-1550.46%-9881.47%-67125.45%---
EBITDA
-44,533-45,97112,684-118,822-16,717-11,708
EBITDA Margin
--7837.31%---
D&A For EBITDA
18,57616,26711,6503,8671,6671,185
EBIT
-63,109-62,2381,034-122,689-18,384-12,893
EBIT Margin
--639.01%---
Source: S&P Global Market Intelligence. Standard template. Financial Sources.